Literature DB >> 21175593

Increased frequency of immunoglobulin (Ig)A-secreting cells following Toll-like receptor (TLR)-9 engagement in patients with Kawasaki disease.

L Giordani1, M G Quaranta, A Marchesi, E Straface, D Pietraforte, A Villani, W Malorni, D Del Principe, M Viora.   

Abstract

Kawasaki disease (KD) is an acute vasculitis affecting mainly infants and children. Human B cells express Toll-like receptor (TLR)-9, whose natural ligands are unmethylated cytosine-guanine dinucleotide (CpG) motifs characteristic of bacterial DNA. The aim of this study was to clarify the pathogenesis of KD analysing the activation status of peripheral blood mononuclear cells (PBMC), focusing on B lymphocyte activation and functions. Ten patients and 10 age-matched healthy donors were recruited from the Bambino Gesù Hospital of Rome, Italy and enrolled into this study. We determined phenotype profile and immunoglobulin (Ig) production of PBMC from KD patients and age-matched controls. We found that the frequency of CD19(+) B lymphocytes and CD19(+) /CD86(+) activated B lymphocytes from KD patients during the acute phase before therapy was increased significantly. Moreover, B lymphocytes of acute-phase KD patients were more prone to CpG oligodeoxynucleotide (ODN) activation compared with the age-matched controls, as assessed by a significant increase of the number of IgA-secreting cells (SC). In the same patients we found a marked increase of IgM, IgG, interleukin (IL)-6 and tumour necrosis factor (TNF)-α production compared with the control group. In addition, in two convalescent KD patients, conventional treatment with intravenous immunoglobulin (IVIG) restored the normal frequency of CD19(+) B cells, the number of IgA-, IgM- and IgG-SC and the production of IL-6 and TNF-α. Our findings indicate that the percentages of peripheral B lymphocytes of acute-phase KD patients are increased and are prone to bacterial activation in terms of increased numbers of IgA-SC and increased production of IL-6 and TNF-α inflammatory cytokines. Thus, our data support the hypothesis of an infectious triggering in KD.
© 2010 The Authors. Clinical and Experimental Immunology © 2010 British Society for Immunology.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21175593      PMCID: PMC3048618          DOI: 10.1111/j.1365-2249.2010.04297.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  33 in total

1.  Surface and cytoplasmic immunoglobulin expression in circulating B-lymphocytes in acute Kawasaki disease.

Authors:  D Shingadia; M O'Gorman; A H Rowley; S T Shulman
Journal:  Pediatr Res       Date:  2001-10       Impact factor: 3.756

2.  Immunoregulatory abnormalities in mucocutaneous lymph node syndrome.

Authors:  D Y Leung; R L Siegel; S Grady; A Krensky; R Meade; E L Reinherz; R S Geha
Journal:  Clin Immunol Immunopathol       Date:  1982-04

3.  A new infantile acute febrile mucocutaneous lymph node syndrome (MLNS) prevailing in Japan.

Authors:  T Kawasaki; F Kosaki; S Okawa; I Shigematsu; H Yanagawa
Journal:  Pediatrics       Date:  1974-09       Impact factor: 7.124

4.  Increased production of serum IgA-class antibody to lipid A in Kawasaki disease.

Authors:  Seiichiro Takeshita; Hiroko Kawase; Tooru Shimizu; Maki Yoshida; Isao Sekine
Journal:  Pediatr Int       Date:  2002-02       Impact factor: 1.524

5.  IgA plasma cell infiltration of proximal respiratory tract, pancreas, kidney, and coronary artery in acute Kawasaki disease.

Authors:  A H Rowley; S T Shulman; C A Mask; L S Finn; M Terai; S C Baker; C A Galliani; K Takahashi; S Naoe; M B Kalelkar; S E Crawford
Journal:  J Infect Dis       Date:  2000-09-08       Impact factor: 5.226

6.  Quantitative expression of toll-like receptor 1-10 mRNA in cellular subsets of human peripheral blood mononuclear cells and sensitivity to CpG oligodeoxynucleotides.

Authors:  Veit Hornung; Simon Rothenfusser; Stefanie Britsch; Anne Krug; Bernd Jahrsdörfer; Thomas Giese; Stefan Endres; Gunther Hartmann
Journal:  J Immunol       Date:  2002-05-01       Impact factor: 5.422

7.  Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association.

Authors:  Jane W Newburger; Masato Takahashi; Michael A Gerber; Michael H Gewitz; Lloyd Y Tani; Jane C Burns; Stanford T Shulman; Ann F Bolger; Patricia Ferrieri; Robert S Baltimore; Walter R Wilson; Larry M Baddour; Matthew E Levison; Thomas J Pallasch; Donald A Falace; Kathryn A Taubert
Journal:  Pediatrics       Date:  2004-12       Impact factor: 7.124

8.  Circulating interleukin 17 is increased in the acute stage of Kawasaki disease.

Authors:  M H Sohn; S Y Noh; W Chang; K M Shin; D S Kim
Journal:  Scand J Rheumatol       Date:  2003       Impact factor: 3.641

Review 9.  Kawasaki syndrome.

Authors:  Jane C Burns; Mary P Glodé
Journal:  Lancet       Date:  2004 Aug 7-13       Impact factor: 79.321

10.  The role of anti-endothelial cell antibodies in Kawasaki disease - in vitro and in vivo studies.

Authors:  E Grunebaum; M Blank; S Cohen; A Afek; J Kopolovic; P L Meroni; P Youinou; Y Shoenfeld
Journal:  Clin Exp Immunol       Date:  2002-11       Impact factor: 4.330

View more
  11 in total

Review 1.  The Roles of Genetic Factors in Kawasaki Disease: A Systematic Review and Meta-analysis of Genetic Association Studies.

Authors:  Xiaochuan Xie; Xiaohan Shi; Meilin Liu
Journal:  Pediatr Cardiol       Date:  2017-11-02       Impact factor: 1.655

Review 2.  Mechanisms of Immune Dysregulation in COVID-19 Are Different From SARS and MERS: A Perspective in Context of Kawasaki Disease and MIS-C.

Authors:  Manpreet Dhaliwal; Rahul Tyagi; Pooja Malhotra; Prabal Barman; Sathish Kumar Loganathan; Jyoti Sharma; Kaushal Sharma; Sanjib Mondal; Amit Rawat; Surjit Singh
Journal:  Front Pediatr       Date:  2022-05-05       Impact factor: 3.569

3.  Clonal expansion and markers of directed mutation of IGHV4-34 B cells in plasmablasts during Kawasaki disease.

Authors:  Arthur J Chang; Sarah Baron; Jonathon Hoffman; Mark D Hicar
Journal:  Mol Immunol       Date:  2022-03-15       Impact factor: 4.174

4.  Genetic epistasis between killer immunoglobulin-like receptors and human leukocyte antigens in Kawasaki disease susceptibility.

Authors:  G Bossi; S Mannarino; M C Pietrogrande; P Salice; R M Dellepiane; A L Cremaschi; G Corana; A Tozzo; C Capittini; A De Silvestri; C Tinelli; A Pasi; M Martinetti
Journal:  Genes Immun       Date:  2015-09-03       Impact factor: 2.676

5.  Combined IFN-β and PLT Detection Can Identify Kawasaki Disease Efficiently.

Authors:  Kan Huijuan; Dong Yaping; Wang Bo; Hou Miao; Qian Guanghui; Yan Wenhua
Journal:  Front Pediatr       Date:  2021-04-22       Impact factor: 3.418

6.  Suppressed plasmablast responses in febrile infants, including children with Kawasaki disease.

Authors:  Meghan Martin; Brian H Wrotniak; Mark Hicar
Journal:  PLoS One       Date:  2018-03-26       Impact factor: 3.240

7.  High Dose Intravenous IgG Therapy Modulates Multiple NK Cell and T Cell Functions in Patients With Immune Dysregulation.

Authors:  Sarah M McAlpine; Sarah E Roberts; John J Heath; Fabian Käsermann; Andrew C Issekutz; Thomas B Issekutz; Beata Derfalvi
Journal:  Front Immunol       Date:  2021-05-19       Impact factor: 7.561

8.  A simple method for assessment of human anti-Neu5Gc antibodies applied to Kawasaki disease.

Authors:  Vered Padler-Karavani; Adriana H Tremoulet; Hai Yu; Xi Chen; Jane C Burns; Ajit Varki
Journal:  PLoS One       Date:  2013-03-08       Impact factor: 3.240

9.  Profiles of responses of immunological factors to different subtypes of Kawasaki disease.

Authors:  Yan Ding; Gang Li; Li-Juan Xiong; Wei Yin; Jie Liu; Fan Liu; Rui-Geng Wang; Kun Xia; Shu-Ling Zhang; Lei Zhao
Journal:  BMC Musculoskelet Disord       Date:  2015-10-23       Impact factor: 2.362

Review 10.  Severe COVID-19, multisystem inflammatory syndrome in children, and Kawasaki disease: immunological mechanisms, clinical manifestations and management.

Authors:  Jayakanthan Kabeerdoss; Rakesh Kumar Pilania; Reena Karkhele; T Sathish Kumar; Debashish Danda; Surjit Singh
Journal:  Rheumatol Int       Date:  2020-11-21       Impact factor: 2.631

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.